Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Olema highlighted two clinical-stage assets targeting ER-positive/HER2-negative breast cancer, with palazestrant in two Phase 3 programs and the first monotherapy readout expected in the fall from OPERA-01. The company also said its KAT6/7 inhibitor showed monotherapy activity in ER-positive/HER2-negative breast cancer and castration-resistant prostate cancer, with combination studies ongoing and planned. The update is informational and pipeline-focused, with limited immediate market impact absent trial data.

Analysis

OLMA is approaching the part of the cycle where narrative starts to matter less than probability-weighted proof. With two late-stage shots on goal, the stock is likely to trade on whether the market believes palazestrant can become a platform backbone rather than a single-asset binary. That matters because in ER+ breast cancer, small efficacy deltas can still be commercially meaningful if they translate into cleaner tolerability and easier combination use, which is often where the real valuation rerating comes from.

The second-order setup is that the market may be underappreciating sequencing risk versus mechanism risk. If the first readout is merely “good but not clearly best-in-class,” the downside can be abrupt because oncology investors typically de-rate precommercial stories once the lead program looks confined to niche use. Conversely, any signal that the asset can extend beyond monotherapy into combination settings would shift the debate from peak-sales skepticism to regimen relevance, which tends to widen the pool of potential strategic interest.

The KAT6/7 program is the more interesting contrarian angle because it creates optionality outside the core breast cancer frame and potentially de-risks the company’s dependence on a single clinical thesis. That said, dual-asset optimism can mask capital intensity: if the company uses positive scientific momentum to lean into multiple studies, dilution risk rises before data de-risks the platform. Over the next 1-3 months, the stock is likely to be driven less by conference commentary than by positioning into the fall catalyst window, so the main trade is volatility around expectations, not fundamentals alone.

The consensus may be too linear in assuming any positive oncology signal is enough. In this subgroup, the market increasingly rewards assets that can either show differentiation in efficacy or create combination utility with a plausible path to partnering. If neither emerges clearly, the upside is capped even with decent data; if one of those shows up, the rerating can be violent because current expectations are still anchored to a single pending readout.

Key Decisions for Investors

• Long OLMA into the fall OPERA-01 readout window, but size as a catalyst trade rather than a core position; use a 4-8 week horizon and treat any pre-data strength as an opportunity to trim into implied optimism.
• Buy OLMA call spreads 2-4 months out to express asymmetric upside into the data without taking full event downside; best if implied volatility remains below the expected binary move.
• Pair trade: long OLMA / short a higher-expectation ER+ breast cancer name with late-stage execution risk if the goal is to isolate readout surprise rather than sector beta.
• If OLMA rallies materially before data, consider selling a portion against the move and re-entering on weakness; the stock should be expected to give back premium if the market senses the readout is already priced.
• Watch for any language suggesting combination expansion or strategic partnering on KAT6/7; that would be the trigger to add, because it broadens the valuation framework from single-asset binary to platform optionality.